GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

GLP-1s may confer greater protection from major adverse cardiovascular events compared with sulfonylureas, ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

GLP-1 receptor agonists may reduce the risk of obesity-related cancers in patients with type 2 diabetes by 7% compared to DPP-4 inhibitors. The study involved 170,030 adults with T2D and obesity, ...

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists reduced mortality vs. DDP-4 ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

CHICAGO -- In patients with type 2 diabetes and obesity, use of GLP-1 receptor agonists was associated with a lower risk of obesity-related cancers and death from any cause, a target trial emulation ...

SAN DIEGO — Patients with obesity and diabetes are at a substantially reduced risk of having a recurrence of atrial fibrillation (AF) after ablation if they are taking a glucagon-like peptide 1 (GLP-1 ...

Although the use of glucagon-like peptide 1 (GLP-1) receptor agonists and other antidiabetic medications continues to increase among pregnant women with type 2 diabetes, current evidence suggests no ...